Search Result

Results for "

Epitope

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (1) Aldehyde Dehydrogenase (ALDH) (1) Amyloid-β (3) Antibiotic (12) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (4) Arenavirus (5) Autophagy (4) Bacterial (11) Biochemical Assay Reagents (7) c-Met/HGFR (1) CD20 (1) CMV (1) DNA/RNA Synthesis (2) Drug Metabolite (4) EBV (7) EGFR (4) Endogenous Metabolite (10) Ferroptosis (1) GABA Receptor (1) GnRH Receptor (11) HBV (1) HCV (1) Histamine Receptor (2) HIV (8) HPV (2) HSV (1) Influenza Virus (10) Interleukin Related (1) Ligands for E3 Ligase (1) Mitophagy (1) Mucin (3) Na+/K+ ATPase (1) Opioid Receptor (1) Orthopoxvirus (1) Parasite (1) RABV (3) Reactive Oxygen Species (1) RSV (2) SARS-CoV (3) Tau Protein (2) Thyroid Hormone Receptor (1) TROP2 (1) Tyrosinase (1)
By Research Areas:	Cancer (39) Cardiovascular Disease (4) Infection (32) Inflammation/Immunology (156) Metabolic Disease (8) Neurological Disease (7)
Oligonucleotides:	Aptamers (1)

120

Inhibitors & Agonists

Screening Libraries

103

Biochemical Assay Reagents

395

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P3813

Tyrosinase (206-214), human	Tyrosinase	Inflammation/Immunology Cancer
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL) .

HY-P99471

Bepranemab UCB 0107	Tau Protein	Neurological Disease
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .

HY-P4020

2F5 epitope	HIV	Others
2F5 epitope, a peptide gp41 (659-671), comprises the entire epitope for one of the three known antibodies capable of neutralizing a broad spectrum of primary HIV-1 isolates and is the only such epitope that is sequential. 2F5 epitope is recognized by broadly neutralizing antibodies 2F5 .

HY-P1881

HPV16-E711-20 epitope	HPV	Cancer
HPV16-E711-20 epitope is a well-known HLA-A ^0201-restricted human cytotoxic T lymphocyte (CTL) epitope* of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. HPV16 CTL epitopes may be good candidates for the development of an effective peptide-based antitumor vaccine .

HY-P5503

Pol (476-484), HIV-1 RT Epitope	HIV	Others
Pol (476-484), HIV-1 RT Epitope is a biological active peptide. (This is a reverse transcriptase (RT) epitope (Pol residues 476-484). Within HIV-1 RT the peptide appears to be the dominant HLA A0201-restricted epitope. Was used to investigate possible mechanisms behind HIV-1 escape from CTL. IV9 is the actual epitope* processed and presented in HIV-1-infected cell lines.)

HY-P5305A

*GAD65(247-266) epitope* TFA**	GABA Receptor	Metabolic Disease
GAD65(247-266) epitope TFA is the T cell epitopes of islet antigens，binding to I-A ^g7 (type I diabetes-associated molecule) competitively with poor affinity. GAD65 refers to Glutamic Acid Decarboxylase 65，involved in the conversion of glutamate to gamma-aminobutyric acid (GABA) .

HY-P99856

Docaravimab	RABV	Infection
Docaravimab is an antibody, targeting *ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope* G-III**. Docaravimab can be used in research of Rabies .

HY-P990073

Davutamig REGN-5093	c-Met/HGFR	Cancer
Davutamig (REGN-5093) is a human immunoglobulin G4-kappa, anti-MET monoclonal antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic .

HY-P4045

HBV Seq2 aa:208-216	HBV	Infection
HBV Seq2 aa:208-216, a HBsAg derived CD8 epitope peptide, is studied as part of Large envelope protein from Hepatitis B virus .

HY-P10663

EBV EBNA3A (379-387)	EBV	Infection Inflammation/Immunology
EBV EBNA3A (379-387) is an antigenic epitope that may elicit the latent-specific CD8 ⁺ T cell response in HLA-B*07:02 ⁺ individuals .

HY-P4032

HCV Peptide (35-44)	HCV	Inflammation/Immunology
HCV Peptide (35-44), a HCV core protein at positions 35 to 44, is a HLA-A2-restricted CTL epitope. HCV Peptide (35-44) inhibits NK cell activity via two distinct mechanisms, directly via KIR2DL2/3, and synergistically via the CD94:NKG2A receptor .

HY-P99551

Tosatoxumab KBSA301; AR-301	Antibiotic	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .

HY-P10607

IALYLQQNW	EBV	Cancer
IALYLQQNW is a specific nonapeptide sequence derived from the tumor-associated antigen latent membrane protein 1 (LMP1) encoded by Epstein-Barr virus (EBV). As a latent T-cell epitope, IALYLQQNW is able to activate EBV-specific cytotoxic T lymphocytes (CTLs), which are able to recognize and kill EBV-infected cells expressing LMP1. IALYLQQNW plays an important role in the immune response against EBV-associated tumors and can be used in the study of Hodgkin's disease and nasopharyngeal carcinoma .

HY-P1762

Influenza NP (147-155)	Influenza Virus	Infection
Influenza NP (147-155) is a K ^d restricted epitope from influenza nucleoprotein .

HY-P1862

HSV-gB2 (498-505)	HSV	Infection
HSV-gB2 (498-505) is an immunodominant epitope from herpes simplex virus (HSV) glycoprotein B residues 498-505, acts as H-2Kb-restricted and HSV-1/2-cross-reactive cytotoxic T-lymphocyte (CTL) recognition epitope .

HY-P1762A

Influenza NP (147-155) (TFA)	Influenza Virus	Infection
Influenza NP (147-155) TFA is a K ^d restricted epitope from influenza nucleoprotein .

HY-P1780

CEF20	CMV	Infection
CEF20 is an HLA-A0201-restricted epitope* from cytomegalovirus pp65 (495-503).

HY-P99628

Futuximab	EGFR	Cancer
Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .

HY-P99968

Clivatuzumab	Mucin	Cancer
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .

HY-P0137

CEF1, Influenza Matrix Protein M1 (58-66)	Influenza Virus	Infection
CEF1, Influenza Matrix Protein M1 (58-66) is an epitope derived from the matrix protein of the influenza A virus .

HY-118380

p-Nitrobenzyl mesylate 4-Nitrobenzyl mesylate; para-Nitrobenzyl mesylate; PNBM	Others	Metabolic Disease
p-Nitrobenzyl mesylate (4-Nitrobenzyl mesylate; para-Nitrobenzyl mesylate) is a reagent used to alkylate phosphorothioates, forming phosphorothioate epitopes that can be recognized by specific antibodies.

HY-P1854

β-Amyloid (1-9)	Amyloid-β	Neurological Disease
β-Amyloid (1-9), an N-terminal fragment of beta amyloid, consists of amino acid residues 1 to 9. β-Amyloid (1-9) contains a B cell epitope, but it does not include T cell epitopes. Omission of residues 1 to 9 from the full-length Alzheimer'sβ-Amyloid peptide 1 to 40 does not prevent the peptide from forming amyloid fibrils or eliminate fibril polymorphism .

HY-P10296

p60 (217–225)	Endogenous Metabolite	Infection
p60 (217–225) is the subdominant epitope of Listeria monocytogenes, which combines with H-2K ^d MHC class I molecules .

HY-P1757

HIV p17 Gag (77-85)	HIV	Infection
HIV p17 Gag (77-85) is an HLA-A0201(A2)-restricted CTL epitope*, used in the research of anti-HIV .

HY-P1837

Influenza HA (518-526)	Influenza Virus	Infection
Influenza HA (518-526) is an H-2K ^d-restricted epitope of the influenza virus hemagglutinin comprised amino acids 533 to 541 .

HY-B1610K

Sodium Citrate Buffer, 0.5M, pH 5.5	Biochemical Assay Reagents	Others
Sodium citrate buffer, 0.5M, pH 5.5, is a commonly used buffer with main components are citric acid and sodium hydrogen phosphate. Sodium citrate buffer 0.5M pH 5.5 is used in heat induced epitope retrieval (HIER) methods to reverse the loss of antigenicity that occurs with some epitopes in formalin-fixed paraffin embedded tissues. Sodium citrate buffer 0.5M pH 5.5 is the preferred solution for most antibodies. .

HY-B1610M

Sodium Citrate Buffer, 0.5M, pH 6.5	Biochemical Assay Reagents	Others
Sodium citrate buffer, 0.5M, pH 6.5, is a commonly used buffer with main components are citric acid and sodium hydrogen phosphate. Sodium citrate buffer, 0.5M, pH 6.5 is used in heat induced epitope retrieval (HIER) methods to reverse the loss of antigenicity that occurs with some epitopes in formalin-fixed paraffin embedded tissues. Sodium citrate buffer, 0.5M, pH 6.5 is the preferred solution for most antibodies .

HY-P1890

CEF14, EBV Rta Protein (28-37)	EBV	Infection
CEF14, EBV Rta Protein (28-37) is the HLA A24-restricted epitope from Epstein-Barr Virus Rta protein (28-37).

HY-P99380

Zanidatamab 1 Publications Verification ZW 25	EGFR	Cancer
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

HY-P99586

Suptavumab REGN2222	RSV	Infection
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .

HY-P10251

HIV gp120 (318-327)	HIV	Infection
HIV gp120 (318-327) is a short sequence of the HIV-1 strain IIIB envelope peptide (rgpgrafvti) that corresponds to the conserved C-terminal region of the glycoprotein. HIV gp120 (318-327) is part of the HIV vaccine V3 peptide epitope, also known as the I10 peptide. However, HIV gp120 (318-327) lacks the A2 anchor residues recognized by epitope-specific CTLs but has structural features that confer promiscuous A2 binding .

HY-P1787

β-Amyloid (4-10)	Amyloid-β	Neurological Disease
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model .

HY-P5482

Epstein-barr virus BRLF1 (134-142)	EBV	Others
Epstein-barr virus BRLF1 (134-142) is a biological active peptide. (HLA-A11 restricted epitope from Epstein-Barr Virus BRLF1 (134-142).)

HY-P10433

EGFRvIII peptide	Apoptosis	Cancer
EGFRvIII peptide is an EGFRvIII-derived epitope for binding to MHC I molecules. EGFRvIII peptide induces apoptosis, and causes specific immune responses against glioblastoma, especially in combination with Flagellin B .

HY-P99454

Azintuxizumab vedotin ABBV-838	Antibody-Drug Conjugates (ADCs)	Cancer
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .

HY-P99859

Donanemab LY3002813	Amyloid-β	Neurological Disease
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .

HY-P5475

BMLF1 (280–288)	EBV	Others
BMLF1 (280–288) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus lytic protein BMLF1 (280-288).)

HY-P5470

LMP2A (426-434)	EBV	Others
LMP2A (426-434) is a biological active peptide. (HLA A2.1-restricted epitope from Epstein-Barr Virus latent membrane protein LMP2 (426-434).)

HY-P1788

Influenza A NP(366-374) Strain A/PR/8/35	Influenza Virus	Infection
Influenza A NP(366-374) Strain A/PR/8/35 is an H2-Db-restricted epitope from Influenza A/PR/8/35 nucleoprotein .

HY-P5930

HOXB7 8–25 MDM2 32-46	Ligands for E3 Ligase	Cancer
HOXB7 8–25 (MDM2 32-46) is an MDM2-derived peptide epitope and can elicit antigen-specifc and tumor-reactive CD4 ⁺ T cell responses .

HY-B1610N

Sodium Citrate Buffer, 0.1M, pH 4.0 1 Publications Verification	Biochemical Assay Reagents	Others
Sodium citrate buffer, 0.1M, pH 4.0, is a commonly used buffer with main components are citric acid and sodium hydrogen phosphate. Sodium citrate buffer, 0.1M, pH 4.0 is used in heat induced epitope retrieval (HIER) methods to reverse the loss of antigenicity that occurs with some epitopes in formalin-fixed paraffin embedded tissues. Sodium citrate buffer, 0.1M, pH 4.0 is the preferred solution for most antibodies . Sodium citrate buffer, 0.1M, pH 4.0 is used in the hydration of liposome film .

HY-P1857

CEF7, Influenza Virus NP (380-388)	Influenza Virus	Infection
CEF7, Influenza Virus NP (380-388) is a HLA-B ^08 restricted influenza virus nucleoprotein epitope*. Influenza virus NP functions as a key adapter molecule between virus and host cell processes .

HY-P2455

LLO (91-99) Listeriolysin O (91-99)	Bacterial	Inflammation/Immunology
LLO (91-99) (Listeriolysin O (91-99)), an exotoxin, is a class I MHC-restricted T-cell epitopes of listeriolysin (LLO). LLO (91-99) is an essential antigen for induction of T-cell mediated immunity in vivo .

HY-P99538

Ublituximab LFB-R603; TG-1101; TGTX-1101	CD20	Cancer
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .

HY-P99634

Gatipotuzumab PankoMab	Mucin	Cancer
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .

HY-B1610J

Sodium Citrate Buffer, 0.5M, pH 5.0	Biochemical Assay Reagents	Others
Sodium citrate buffer, 0.5M, pH 5.0, is a commonly used buffer with main components are citric acid and sodium hydrogen phosphate. Sodium citrate buffer, 0.5M, pH 5.0 is used in heat induced epitope retrieval (HIER) methods to reverse the loss of antigenicity that occurs with some epitopes in formalin-fixed paraffin embedded tissues. Sodium citrate buffer, 0.5M, pH 5.0 is the preferred solution for most antibodies . Sodium citrate buffer, 0.5M, pH 5.0 is used as solution for captisol in animal tumor models .

HY-P1571

Nucleoprotein (396-404) NP 396	Arenavirus	Inflammation/Immunology
Nucleoprotein (396-404) is the 396 to 404 fragment of lymphocytic choriomeningitis virus (LCMV). Nucleoprotein (396-404) is the H-2D(b)-restricted immunodominant epitope and can be used as a molecular model of viral antigen .

HY-P1885

HIV gag peptide (197-205)	HIV	Infection
HIV gag peptide (197-205) is a H-2K ^d-restricted epitope derived from the p24 portion of the HIV-1 gag protein, consists of amino acids 197-205 (AMQMLKETI) .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-160060

MA3 aptamer sodium	Mucin	Cancer
MA3 aptamer sodium is an 86-base long DNA aptamer targeting the mucin MUC1. MA3 aptamer sodium binds to the peptide epitope of mucin 1 (MUC1) with a Kd of 38.3 nM and has minimal cross-reactivity with albumin .

Cat. No.	Product Name

HY-L0119V

Asinex PPI Pre-Plated Library

3,253 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.

HY-L913

Tyrosine Focused Covalent Fragment Library

124 compounds

Recently, significant advancements in tyrosine-targeting electrophiles have primarily occurred in the field of protein-protein interactions (PPIs), where cysteine residues are often underrepresented and novel chemistries are needed to address these interfaces. In this context, tyrosines are frequently more accessible compared to more buried binding sites. Moreover, they are commonly found at "hot spots," which are functional epitopes of PPIs, with 12.3% of the residues consisting of tyrosines. This prevalence is likely due to the hydrophobic nature of tyrosine, its ability to participate in aromatic π-interactions, and its capacity for hydrogen bonding. Beyond PPIs, some progress has also been made in covalent tyrosine targeting in other areas where more commonly addressed side chains are lacking. Even though tyrosine has a slightly lower pKa value compared to the protonated lysine side chain (approximately 10 vs. 10.5 for the unprotected amino acid side chains), significantly less progress has been made in the development of tyrosine-targeted covalent ligands compared to lysine. This is likely due to the reduced flexibility of the tyrosine side chain and the greater steric hindrance of its hydroxy group, which makes it more challenging to adopt suitable reaction geometries.

Through careful selection, we constructed a structural filter containing over 110 electrophilic groups. By analyzing the electrophilic fragments selected by the structural filter, we removed any molecules with trivial or undesirable structural features. Ultimately, we obtained 124 fragment molecules which can target tyrosine residue and can be used for fragment-based covalent drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P99471

Bepranemab UCB 0107	Tau Protein	Neurological Disease
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research .

HY-P99551

Tosatoxumab KBSA301; AR-301	Antibiotic	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent .

HY-P99968

Clivatuzumab	Mucin	Cancer
Clivatuzumab is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers .

HY-P99380

Zanidatamab 1 Publications Verification ZW 25	EGFR	Cancer
Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .

HY-P99586

Suptavumab REGN2222	RSV	Infection
Suptavumab (REGN2222) is a human monoclonal antibody. Suptavumab can bind and block a conserved epitope on RSV A and B subtypes. Suptavumab can be used for the research of RSV infection .

HY-P990814

*Anti-SARS-CoV-2 S protein Antibody (RBD epitope* B, SARS2-34)**	Inhibitory Antibodies	Others
Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to SARS-CoV-2 S protein. The recommend isotype control of Anti-SARS-CoV-2 S protein Antibody (RBD epitope B, SARS2-34): Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-P990815

*Anti-SARS-CoV-2 S protein Antibody (RBD epitope* A, SARS2-01)**	Inhibitory Antibodies	Others
Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01) is a kind of mouse IgG1 kappa in vivo mouse antibody, targeting to SARS-CoV-2 S protein. The recommend isotype control of Anti-SARS-CoV-2 S protein Antibody (RBD epitope A, SARS2-01): Mouse IgG1 kappa, Isotype Control (HY-P99977).

HY-P99856

Docaravimab	RABV	Infection
Docaravimab is an antibody, targeting *ERA (Evelyn-Rockitniki-Abelseth) glycoprotein ectodomain epitope* G-III**. Docaravimab can be used in research of Rabies .

HY-P990073

Davutamig REGN-5093	c-Met/HGFR	Cancer
Davutamig (REGN-5093) is a human immunoglobulin G4-kappa, anti-MET monoclonal antibody targeting two different nonoverlapping epitopes on MET. Davutamig is an antineoplastic .

HY-P99628

Futuximab	EGFR	Cancer
Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .

HY-P99454

Azintuxizumab vedotin ABBV-838	Antibody-Drug Conjugates (ADCs)	Cancer
Azintuxizumab vedotin (ABBV-838) is an antibody–drug conjugate (ADC) targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells .

HY-P99859

Donanemab LY3002813	Amyloid-β	Neurological Disease
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .

HY-P99538

Ublituximab LFB-R603; TG-1101; TGTX-1101	CD20	Cancer
Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .

HY-P99634

Gatipotuzumab PankoMab	Mucin	Cancer
Gatipotuzumab (PankoMab) is a humanized monoclonal antibody which recognizes the tumor-specific epitope of mucin-1 (TA-MUC1). Gatipotuzumab reveals a potent tumor-specific antibody-dependent cell cytotoxicity (ADCC) .

HY-P99435

Amubarvimab BRII-196	SARS-CoV	Infection
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a K_D of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants .

HY-P99727

Mazorelvimab SYN023	RABV	Infection
Mazorelvimab (SYN023) is a combination of CTB011 and CTB012 humanized monoclonal antibodies cocktail against rabies virus (RABV). Mezagitamab binds to non-overlapping epitopes on RABV glycoprotein (G). Mezagitamab has potential application in the prevention of rabies .

HY-P99306

Modotuximab DS 1024	EGFR	Cancer
Modotuximab (DS 1024) is an IgG1κ-type chimeric antibody targeting human EGFR protein. Modotuximab binds non-overlapping epitopes on domain III of EGFR, a domain that is intact in EGFRvIII. Modotuximab has antitumor activity in vivo .

HY-P99559

Tilogotamab GEN-1029; HexaBody-DR5/DR5; Hx-DR5-01/05	Inhibitory Antibodies	Cancer
Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM) .

HY-P99513

Zamerovimab CTB011; SYN023	RABV	Infection
Zamerovimab (CTB011; SYN023) is a mixture of human monoclonal antibodies consisting of CTB011 and CTB012. Zamerovimab binds to non-overlapping epitopes on rabies virus (RABV) glycoprotein, where CTB011 binds to antigenic site III. Zamerovimab can be used in rabies studies .

HY-P990094

Trabikibart CSL311	Inhibitory Antibodies	Inflammation/Immunology
Trabikibart (CSL311), a βc (CSF2RB)-specific, fully human monoclonal antibody, binds to a unique epitope that is specific to the cytokine-binding site of the human βc receptor. Trabikibart has picomolar binding affinity for the human βc receptor. Trabikibart is a potent inhibitor of the combined effects of IL-3, GM-CSF and IL-5 on the survival of eosinophils. Trabikibart has the potential for chronic inflammatory diseases research .

HY-145642

Masavibart ZRC3308-A7	SARS-CoV	Infection
Masavibart (ZRC3308-A7) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Masavibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Masavibart can be used in combination with ZRC3308-B10 (HY-145643) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-145643

Nepuvibart ZRC3308-B10	SARS-CoV	Infection
Nepuvibart (ZRC3308-B10) is an anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Nepuvibart shows good binding affinity to a non-competing epitope on the RBD of the SARS-CoV-2 spike protein. Nepuvibart can be used in combination with ZRC3308-A7 (HY-145642) at a ratio of 1:1, which is effective for the prevention of COVID-19 and the early stage of COVID-19 before the development of severe disease .

HY-P99045

Sacituzumab	ADC Antibody TROP2	Cancer
Sacituzumab is a humanized IgG1 monoclonal antibody targeting Trophoblast cell surface antigen 2 (TROP2). Sacituzumab demonstrates a lack of antitumor effects alone and does not inhibit the function of TROP-2 during tumor metastasis, binding to the linear epitopes of TROP-2 protein. Sacituzumab is used for the synthesis of antibody-drug conjugates (ADC) drugs. Antibody-drug conjugates with sacituzumab (sacituzumab govitecan) (HY-132254) targeting TROP-2 have been approved for the field of triple-negative breast cancer .

HY-P990090

Rademikibart CBP-201	Interleukin Related	Inflammation/Immunology
Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and TARC production in PBMCs. Rademikibart has the potential for moderate-to-severe Th2 inflammatory diseases research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-P0277

Carcinoembryonic antigen peptide 1 CEA peptide	Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields Cancer	Others
Carcinoembryonic antigen peptide 1 (CEA peptide) is a carcinoembryonic antigen (CEA)-derived peptide. Carcinoembryonic antigen peptide 1 is a potential HLA-A0201-restricted CTL epitope* that can be used for the study of CTL-mediated epithelial-derived cancers .

HY-N11140

Glu-Lys	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	Others
Glu-Lys is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-N10510

Blood group A antigen tetraose type 5 A-Tetrasaccharide	Structural Classification Natural Products Polysaccharides Classification of Application Fields Other Diseases Endogenous metabolite Disease Research Fields Saccharides	Others
Blood group A antigen tetraose type 5 (A-Tetrasaccharide) is a tetrasaccharide and a blood group specific oligosaccharide, inhibits the binding of anti-A antibody to blood group A substance. Blood group A antigen tetraose type 5 can be isolated from polar bear milk samples .

Cat. No.	Product Name	Chemical Structure

HY-P4229

([D8]Val7,10)-C-Peptide (human)
([D8]Val7,10)-C-Peptide (human) is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83697

	6X His-tag Antibody (YA3432) 6 His Epitope tag antibody; Hexa His tag antibody; HHHHHH Epitope tag antibody; HHHHHH tag antibody; His tag antibody; Polyhistidine Tag antibody;	WB, IHC-P, ICC/IF, IP, FC	Species independent
	6X His-tag Antibody is a non-conjugated and Rabbit origined monoclonal antibody. It can be used for WB, IF-Cell, IHC-P, FC, IP assays.

HY-P80948B

	HA tag Antibody (YA3393) HA Epitope tag antibody; HA1; HA2; hemagglutinin antibody	WB, ICC/IF, IP	Species independent
	Anti-HA tag Antibody is a non-conjugated and Rabbit origined monoclonal antibody. It can be used for WB, IF-Cell, IP assays.

HY-P83702

	Cytokeratin 17 Antibody (YA3438) 39.1 antibody; CK 17 antibody; CK17 antibody; CK-17 antibody; Cytokeratin-17 antibody; K17 antibody; K1C17_HUMAN antibody; Keratin 17 antibody; keratin 17 Epitope S1 antibody; keratin 17 Epitope S2 antibody; keratin 17 Epitope S4 antibody; Keratin 17, type I antibody; Keratin antibody; Keratin type I cytoskeletal 17 antibody; keratin, type i cytoskeletal 17 [version 1] antibody; Keratin-17 antibody; KRT17 antibody; PC antibody; PC2 antibody; PCHC1 antibody; type I cytoskeletal 17 antibody	WB, IHC-P, ICC/IF	Human, Mouse, Rat
	Cytokeratin 17 Antibody (YA3438) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3438), targeting Cytokeratin 17, with a predicted molecular weight of 48 kDa (observed band size: 48 kDa). Cytokeratin 17 Antibody (YA3438) can be used for WB, IF-Cell, IF-Tissue, IHC-P experiment in human, Mouse, Rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification